Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06636175
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-08
Brief Title:
64Cu-LLP2A for Imaging Hematologic Malignancies
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Early Phase I Evaluation of 64Cu-LLP2A for Imaging Hematologic Malignancies Part B
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase of the protocol protocol part B seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A Additionally the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma MM low-grade lymphoma or MM and lymphoma patients who are status post bone marrow transplant BMT with negative imaging and suspected recurrence
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None